Chlorproguanil−Dapsone−Artesunate versus Artemether−Lumefantrine: A Randomized, Double-Blind Phase III Trial in African Children and Adolescents with Uncomplicated Plasmodium falciparum Malaria

Zul Premji; Rich E. Umeh; Seth Owusu-Agyei; Fabian Esamai; Emmanuel U. Ezedinachi; Stephen Oguche; Steffen Borrmann; Akintunde Sowunmi; Stephan Duparc; Paula L. Kirby; Allan Pamba; Lynda Kellam; Robert Guiguemdé; Brian Greenwood; Stephen A. Ward; Peter A. Winstanley

Download: PDF | Citation | XML
EzReprint New & improved!

Metrics info

Average Rating (0 User Ratings)

- Currently 0/5 Stars.
See all categories
1. Insight
  - Currently 0/5 Stars.
2. Reliability
  - Currently 0/5 Stars.
3. Style
  - Currently 0/5 Stars.
Rate This Article

Rate This Article

Please follow our guidelines for rating and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:

Remarks that could be interpreted as allegations of misconduct
Unsupported assertions or statements
Inflammatory or insulting language

Compose Your Annotation

Insight

Reliability

Style

Enter your comment title Enter your comment

Declare any competing interests.

No, I don't have any competing interests to declare.
Yes, I have competing interests to declare (enter below):

Ratings can include the following markup tags:

Emphasis: ''italic'' '''bold''' '''''bold italic'''''

Other: ^^^superscript^^ ~~_subscript~~

Metrics info

Average Rating (0 User Ratings)

Related Content

Share this Article info

Chlorproguanil−Dapsone−Artesunate versus Artemether−Lumefantrine: A Randomized, Double-Blind Phase III Trial in African Children and Adolescents with Uncomplicated Plasmodium falciparum Malaria

Article Usage info

Citations info

Cited in

Other Indicators of Impact info

Average Rating

Reader Comments

Bookmarked in

Blog Coverage

Trackbacks

Rate This Article